MOVING
What it found
The trial ended early for another reason (see below).
6 months
| Group | n | Value |
|---|---|---|
| fingolimod | 5 | median decrease, 15.7 ms |
| IFN-β 1b | 4 | median increase, 8.15 ms |
p = < 0.001 for interaction
Total participants: 15
Read by software from the paper's abstract
What was tested
Treatment tested
Compared with
- Interferon beta-1b
Interferon alpha/beta receptor agonist
What it measured
Main measures
Latency of multifocal VEP (mVEP) of the affected eye after 6 months therapy compared to baseline
Myelin repair
Other measures (1)
Different secondary outcomes regarding visual system etc.
Who could take part
Relapsing MS
Inclusion: • relapsing-remitting Multiple sclerosis (MS) or clinically isolated syndrom Exclusion: • Know contraindications againts therapy with Fingolimod (Gilenya®) or Interferon beta-1b Extavia®
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess whether an early therapy with Fingolimod (Gilenya®) after Optic neuritis (ON) leads to a more favourable visual outcome after 6 months compared to a therapy with Interferon beta-1b (Extavia®).
Papers
Results
Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.BMC Neurol · 2020
Per protocol analysis of the primary endpoint revealed a significantly larger reduction of mfVEP latency at 6 months compared to baseline with fingolimod treatment (n = 5; median decrease, 15.7 ms) than with IFN-β 1b treatment (n = 4; median increase, 8.15 ms) (p < 0.001 for interaction).
Read by software from the paper's abstract
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Jul 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error